Silence Therapeutics PLC Silence to Present at Scientific Conferences

TIDMSLN

Silence Therapeutics PLC

26 March 2018

Silence Therapeutics to Present at Upcoming Scientific Conferences in March and April 2018

London, 26(th) March 2018

Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that that the company is scheduled to present at the following scientific conferences in March and April 2018.

Third Annual Oligonucleotide & Peptide Therapeutics (OPT)

March 26-28, 2018, Boston Marriott Cambridge, Cambridge, Boston, MA, US

Marie Lindholm, Head of Technology Innovation, will present on Tuesday March 27 at 1.20pm EDT. The presentation is entitled 'Development of Novel Therapies Using Advanced GalNAc-siRNA Technology'.

Drug Discovery for Rare Diseases Symposium at OPT Congress

March 28, 2018, Boston Marriott Cambridge, Cambridge, Boston, MA, US

Torsten Hoffmann, COO, will present a case study on the company and its science entitled 'Identification and Development of SLN124, a Conjugated GalNAc-siRNA Therapeutic for the Treatment of Iron Overload Disorders' at 4.35pm EDT.

4(th) Annual Oligo 2018 Oxford

April 10, 2018, St Edmund Hall, Oxford, UK

Adrien Weingaertner, Group Leader, Drug Delivery, will make a presentation at 5.30pm BST. The presentation is entitled 'Development of innovative hepatocyte-targeted siRNA conjugates for the treatment of liver-related disorders'.

9th Clinical Trials Innovation Programme

April, 26-27, 2018, Höchster Hof Hotel GmbH, Frankfurt, Germany

Manuela Aleku, Head of Non-Clinical Development, will be presenting on Thursday April 26, 2018 at 9am CEST.

Enquiries:

 
 Silence Therapeutics plc            Tel: [phone] 
  Ali Mortazavi, Chief Executive      6900 
  Officer 
  David Ellam, Chief Financial 
  Officer 
 
   Peel Hunt LLP (Nominated            Tel: [phone] 
   Adviser and Broker)                 8900 
   James Steel/Oliver Jackson 
 Media Enquiries: 
  Optimum Strategic Communications     Tel: [phone] 
  Mary Clark/ Eva Haas/Hollie          1788 
  Vile 
  [e-mail] 
 IR Enquires - US                    Tel: [phone] 
  Burns McClellan                     0006 
  John Grimaldi 
 

Notes to Editors

About Silence Therapeutics plc

Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. For more information, please visit: http://www.silence-therapeutics.com/

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRALLFFRVAIVFIT

(END) Dow Jones Newswires

March 26, 2018 02:00 ET (06:00 GMT)